These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The FDA and drug safety: a proposal for sweeping changes. Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL. Arch Intern Med; 2006 Oct 09; 166(18):1938-42. PubMed ID: 17030825 [Abstract] [Full Text] [Related]
24. Vioxx's history and the need for better procedures and better testing. Gilhooley M. Seton Hall Law Rev; 2007 Oct 09; 37(4):941-68. PubMed ID: 18363218 [No Abstract] [Full Text] [Related]
25. FDA attempting to overcome major roadblocks in monitoring drug safety. Zielinski SL. J Natl Cancer Inst; 2005 Jun 15; 97(12):872-3. PubMed ID: 15956645 [No Abstract] [Full Text] [Related]
26. The Supreme Court, preemption, and malpractice liability. Kesselheim AS, Studdert DM. N Engl J Med; 2009 Feb 05; 360(6):559-61. PubMed ID: 19196672 [No Abstract] [Full Text] [Related]
27. Drug-review deadlines and safety problems. Nardinelli C, Lanthier M, Temple R. N Engl J Med; 2008 Jul 03; 359(1):95-6; author reply 96-8. PubMed ID: 18596282 [No Abstract] [Full Text] [Related]
28. The marketplace can't give us the drug safety data we need. Avorn J. MedGenMed; 2007 Feb 09; 9(1):29. PubMed ID: 17435636 [No Abstract] [Full Text] [Related]
29. Ensuring the safety of genotech drugs through implied warranty theory. Serra WM. Am J Law Med; 1997 Feb 09; 23(2-3):363-81. PubMed ID: 9262761 [No Abstract] [Full Text] [Related]
30. Deterring inefficient pharmaceutical litigation: an economic rationale for the FDA regulatory compliance defense. Viscusi WK, Rowland SR, Dorfman HL, Walsh CJ. Spec Law Dig Health Care Law; 1996 Mar 09; (205):9-52. PubMed ID: 10156421 [No Abstract] [Full Text] [Related]
31. The unfinished business of U.S. drug safety regulation. Evans BJ, Flockhart DA. Food Drug Law J; 2006 Mar 09; 61(1):45-63. PubMed ID: 16838457 [No Abstract] [Full Text] [Related]
35. FDA's regulation of prescription drug labeling: a role for implied preemption. Kendrick LC. Food Drug Law J; 2007 Mar 09; 62(1):227-47. PubMed ID: 17444031 [No Abstract] [Full Text] [Related]
36. Pharmaceuticals and medical devices: FDA oversight. Issue brief. Thomson Reuters/West. Issue Brief Health Policy Track Serv; 2011 Jan 03; ():1-39. PubMed ID: 21374841 [No Abstract] [Full Text] [Related]
37. Impossible? Outlawing state safety laws for generic drugs. Glantz LH, Annas GJ. N Engl J Med; 2011 Aug 25; 365(8):681-3. PubMed ID: 21830958 [No Abstract] [Full Text] [Related]
38. Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration. Ball R, Horne D, Izurieta H, Sutherland A, Walderhaug M, Hsu H. Pediatrics; 2011 May 25; 127 Suppl 1():S31-8. PubMed ID: 21502249 [Abstract] [Full Text] [Related]
39. Drug safety and drug efficacy: two sides of the same coin. Young RC, Friedman MA, Schilsky RL, Sigal EV. Clin Cancer Res; 2007 May 01; 13(9):2533-4. PubMed ID: 17473179 [No Abstract] [Full Text] [Related]
40. How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications. Ehrenpreis ED, Ciociola AA, Kulkarni PM, FDA-Related Matters Committee of the American College of Gastroenterology. Am J Gastroenterol; 2012 Apr 01; 107(4):501-4. PubMed ID: 22475958 [No Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]